What is Bio SB?
Bio SB, Inc. operates at the intersection of advanced biotechnology and clinical diagnostics, specializing in the development and distribution of high-precision antibodies and detection systems for immunohistochemistry (IHC). By maintaining rigorous adherence to international quality standards, including FDA QSR, CE IVD, and ISO13485:2016 certifications, the company provides essential tools for molecular pathology, cancer research, and microbiology. Their product portfolio is engineered to meet the exacting requirements of modern laboratories, facilitating accurate diagnostic outcomes and supporting complex genetic research applications. Through its commitment to environmentally friendly ancillaries and validated IVD technologies, Bio SB serves as a foundational partner for research institutions and clinical diagnostic facilities worldwide.
How much funding has Bio SB raised?
Bio SB has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Bio SB
PPP
Public-Private Partnership
What's next for Bio SB?
Following this late-stage financing, Bio SB is poised to scale its production capabilities and expand its footprint in the global diagnostics market. The strategic allocation of these funds will likely prioritize the enhancement of their proprietary antibody pipeline and the optimization of their detection system platforms. As the demand for precise, rapid diagnostic tools continues to rise in the wake of evolving oncological and immunological research needs, Bio SB is strategically aligned to capture additional market share. The company's focus on maintaining high regulatory standards will remain a key competitive advantage, ensuring that their next phase of growth is supported by both technological innovation and operational excellence in the highly regulated medical device industry.
See full Bio SB company page
